stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Return on assets
Telix Pharmaceuticals Limited's return on assets over the twelve months to 30 June 2026 was 0.00%, up 0.7 percentage points from fiscal 2025 (−0.68%). That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −0.68% | (6.25) |
| FY2024 | 5.57% | 5.57 |
| FY2023 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)